Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Change log
Hu, Zhi 
Mao, Jian-Hua 
Curtis, Christina 
Huang, Ge 
Gu, Shenda 

BACKGROUND: High mitotic activity is associated with the genesis and progression of many cancers. Small molecule inhibitors of mitotic apparatus proteins are now being developed and evaluated clinically as anticancer agents. With clinical trials of several of these experimental compounds underway, it is important to understand the molecular mechanisms that determine high mitotic activity, identify tumor subtypes that carry molecular aberrations that confer high mitotic activity, and to develop molecular markers that distinguish which tumors will be most responsive to mitotic apparatus inhibitors. METHODS: We identified a coordinately regulated mitotic apparatus network by analyzing gene expression profiles for 53 malignant and non-malignant human breast cancer cell lines and two separate primary breast tumor datasets. We defined the mitotic network activity index (MNAI) as the sum of the transcriptional levels of the 54 coordinately regulated mitotic apparatus genes. The effect of those genes on cell growth was evaluated by small interfering RNA (siRNA). RESULTS: High MNAI was enriched in basal-like breast tumors and was associated with reduced survival duration and preferential sensitivity to inhibitors of the mitotic apparatus proteins, polo-like kinase, centromere associated protein E and aurora kinase designated GSK462364, GSK923295 and GSK1070916, respectively. Co-amplification of regions of chromosomes 8q24, 10p15-p12, 12p13, and 17q24-q25 was associated with the transcriptional upregulation of this network of 54 mitotic apparatus genes, and we identify transcription factors that localize to these regions and putatively regulate mitotic activity. Knockdown of the mitotic network by siRNA identified 22 genes that might be considered as additional therapeutic targets for this clinically relevant patient subgroup. CONCLUSIONS: We define a molecular signature which may guide therapeutic approaches for tumors with high mitotic network activity.

Breast cancer, Mitotic index, Novel therapeutics, Predictive biomarker, Aurora Kinases, Breast Neoplasms, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Chromosomal Proteins, Non-Histone, Female, Gene Amplification, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Genome, Human, Humans, Kaplan-Meier Estimate, Mitosis, Prognosis, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins, RNA Interference, Small Molecule Libraries, Treatment Outcome, Polo-Like Kinase 1
Journal Title
Breast Cancer Res
Conference Name
Journal ISSN
Volume Title
Springer Science and Business Media LLC
MRC (MR/N501876/1)
Cancer Research Uk (None)
Cancer Research UK (CB4140)
Cancer Research UK (unknown)
Cancer Research UK (C507/A16278)
Cancer Research UK (unknown)
Cancer Research UK (60098573)
Cancer Research UK (unknown)
Department of Health (via National Institute for Health Research (NIHR)) (unknown)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Cancer Research Uk (None)
Cambridge University Hospitals NHS Foundation Trust (CUH) (RG51913)
MRC (MR/N501876/1)
MRC (MC_UU_12022/10)